BFEC
REGN icon

Benjamin F. Edwards & Company’s Regeneron Pharmaceuticals REGN Stock Holding History

Benjamin F. Edwards & Company’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$3.13M Buy
2,980
+612
+26% +$593K 0.06% 292
2024
Q1 		$2.28M Buy
2,368
+807
+52% +$767K 0.04% 343
2023
Q4 		$1.37M Buy
1,561
+322
+26% +$265K 0.03% 420
2023
Q3 		$1.02M Buy
1,239
+1,178
+1,931% +$926K 0.04% 367
2023
Q2 		$44K Buy
61
+58
+1,933% +$44.7K ﹤0.01% 1124
2023
Q1 		$2K Hold
3
– – ﹤0.01% 1688
2022
Q4 		$2K Sell
3
-120
-98% -$88.5K ﹤0.01% 1742
2022
Q3 		$85K Sell
123
-11
-8% -$6.92K ﹤0.01% 908
2022
Q2 		$79K Sell
134
-101
-43% -$65.7K ﹤0.01% 933
2022
Q1 		$164K Sell
235
-20
-8% -$12.7K 0.01% 738
2021
Q4 		$161K Buy
255
+30
+13% +$18.4K 0.01% 752
2021
Q3 		$136K Buy
225
+33
+17% +$20.5K 0.01% 780
2021
Q2 		$107K Sell
192
-168
-47% -$85.1K 0.01% 829
2021
Q1 		$170K Buy
360
+37
+11% +$18K 0.01% 716
2020
Q4 		$156K Buy
323
+112
+53% +$60.5K 0.01% 706
2020
Q3 		$118K Sell
211
-462
-69% -$280K 0.01% 705
2020
Q2 		$420K Buy
673
+532
+377% +$302K 0.03% 404
2020
Q1 		$69K Sell
141
-53
-27% -$21.9K 0.01% 786
2019
Q4 		$73K Sell
194
-562
-74% -$189K 0.01% 871
2019
Q3 		$210K Buy
756
+731
+2,924% +$216K 0.02% 548
2019
Q2 		$8K Hold
25
– – ﹤0.01% 1497
2019
Q1 		$10K Hold
25
– – ﹤0.01% 1323
2018
Q4 		$9K Buy
+25
New +$9.15K ﹤0.01% 1321
2018
Q2 		– Sell
-50
Closed -$17K – 1643
2018
Q1 		$17K Hold
50
– – ﹤0.01% 1117
2017
Q4 		$19K Buy
+50
New +$20.3K ﹤0.01% 1049
2014
Q1 		– Sell
-8
Closed -$2K – 953
2013
Q4 		$2K Buy
+8
New +$2.3K ﹤0.01% 883

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Benjamin F. Edwards & Company's REGN Position: Q2 2024 in Review

Benjamin F. Edwards & Company increased its Regeneron Pharmaceuticals (REGN) stake by 26% in Q2 2024, buying an estimated $593K and bringing the position to 2,980 shares worth $3.13M. The position accounts for 0.06% of the portfolio, ranked #292.

Benjamin F. Edwards & Company first reported a position in REGN in Q4 2013 and has held it in 26 quarters since. 1,334 funds tracked by Wall St. Rank hold REGN as of Q2 2024.

  • Benjamin F. Edwards & Company held 2,980 shares of Regeneron Pharmaceuticals worth $3.13M as of Q2 2024.
  • Benjamin F. Edwards & Company bought 612 Regeneron Pharmaceuticals shares in Q2 2024, an estimated $593K.
  • Regeneron Pharmaceuticals made up 0.06% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #292 holding.
  • Benjamin F. Edwards & Company first reported a position in Regeneron Pharmaceuticals in Q4 2013 and has held it in 26 quarters since.
  • 1,334 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.